Combination therapies for treatment of cancer
AssigneeSumitomo Dainippon Pharma Oncology, Inc.
InventorsDavid J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
Life of this patent
Estimating the term…
Abstract
Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
Claims17
A method for treating myelodysplastic syndrome (MDS) in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of the following therapeutic agents:
- i) alvocidib, or a pharmaceutically acceptable salt thereof;
- and
- ii) a DNA methyltransferase inhibitor selected from azacitidine, or a pharmaceutically acceptable salt thereof, or decitabine, or a pharmaceutically acceptable salt thereof.
2-8. (canceled)
12-15. (canceled)
A kit comprising alvocidib, or a pharmaceutically acceptable salt thereof, a DNA methyltransferase inhibitor selected from azacitidine, or a pharmaceutically acceptable salt thereof, and decitabine, or a pharmaceutically acceptable salt thereof, and instructions for administering the alvocidib, or a pharmaceutically acceptable salt thereof, and the DNA methyltransferase inhibitor to a mammal in need of treatment for MDS.
17-19. (canceled)
A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient, alvocidib, or a pharmaceutically acceptable salt thereof, and a DNA methyltransferase inhibitor selected from azacitidine, or a pharmaceutically acceptable salt thereof, or decitabine, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.